Zanamivir - CAS 139110-80-8
Catalog number: B0084-083764
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C12H20N4O7
Molecular Weight:
332.31
COA:
Inquire
Targets:
Influenza Virus
Description:
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-083764 1 g $469 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
GG167; GG 167; GG-167
MSDS:
Inquire
InChIKey:
ARAIBEBZBOPLMB-UFGQHTETSA-N
InChI:
InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
Canonical SMILES:
CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N
1.Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.
Okomo-Adhiambo M1, Mishin VP1, Sleeman K1, Saguar E2, Guevara H2, Reisdorf E3, Griesser RH3, Spackman KJ4, Mendenhall M4, Carlos MP5, Healey B5, St George K6, Laplante J6, Aden T7, Chester S7, Xu X1, Gubareva LV8. Antiviral Res. 2016 Apr;128:28-35. doi: 10.1016/j.antiviral.2016.01.009. Epub 2016 Jan 22.
BACKGROUND: Monitoring influenza virus susceptibility to neuraminidase (NA) inhibitors (NAIs) is vital for detecting drug-resistant variants, and is primarily assessed using NA inhibition (NI) assays, supplemented by NA sequence analysis. However, differences in NI testing methodologies between surveillance laboratories results in variability of 50% inhibitory concentration (IC50) values, which impacts data sharing, reporting and interpretation. In 2011, the Centers for Disease Control and Prevention (CDC), in collaboration with the Association for Public Health Laboratories (APHL) spearheaded efforts to standardize fluorescence-based NI assay testing in the United States (U.S.), with the goal of achieving consistency of IC50 data.
2.Susceptibility of influenza viruses circulating in Western Saudi Arabia to neuraminidase inhibitors.
Tolah AM1, Azhar EI, Hashem AM. Saudi Med J. 2016 Apr;37(4):461-5. doi: 10.15537/smj.2016.4.14837.
OBJECTIVES: To investigate the sensitivity of circulating influenza viruses in Western Saudi Arabia to neuraminidase inhibitors (NAIs); mainly, zanamivir and oseltamivir.
3.Characterization of Neuraminidase Inhibitors in Korean Papaver rhoeas Bee Pollen Contributing to Anti-Influenza Activities In Vitro.
Lee IK1, Hwang BS1, Kim DW1, Kim JY1, Woo EE1, Lee YJ1, Choi HJ2, Yun BS1. Planta Med. 2016 Feb 5. [Epub ahead of print]
The active constituents of Korean Papaver rhoeas bee pollen conferring neuraminidase inhibitory activities (H1N1, H3N2, and H5N1) were investigated. Six flavonoids and one alkaloid were isolated and characterized by nuclear magnetic resonance and mass spectrometry data. These included kaempferol-3-sophoroside (1), kaempferol-3-neohesperidoside (2), kaempferol-3-sambubioside (3), kaempferol-3-glucoside (4), quercetin-3-sophoroside (5), luteolin (6), and chelianthifoline (7). All compounds showed neuraminidase inhibitory activities with IC50 values ranging from 10.7 to 151.1 µM. The most potent neuraminidase inhibitor was luteolin, which was the dominant content in the ethyl acetate fraction. All tested compounds displayed noncompetitive inhibition of H3N2 neuraminidase. Furthermore, compounds 1-7 all reduced the severity of virally induced cytopathic effects as determined by the Madin-Darby canine kidney cell-based assay showing antiviral activity with IC50 values ranging from 10.
4.[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Hishiki H, Ishiwada N, Naito S, Nagasawa K, Someya T, Inoue N, Haraki M, Kurosaki T, Kameoka Y, Suzuki K. Jpn J Antibiot. 2015 Dec;68(6):337-43.
We investigated the clinical symptoms of 206 pediatric patients with influenza virus infection and compared them among oseltamivir-treated, zanamivir-treated, and laninamivir-treated groups in 2013/2014 influenza season. The drug compliance of each neuraminidase inhibitor was good in all three groups. Although the duration of fever after administration of the first dose of each neuraminidase inhibitor were significantly prolonged in the patient with influenza B infection than in the patient with influenza A infection, no statistically significant difference in the clinical efficacy and the side effect among three groups were found. The number of biphasic fever episodes in patients treated with neuraminidase inhibitor was rare (two episodes of oseltamivir-treated group and one episode of zanamivir-treated group). In conclusion, under the good drug compliance, the efficacy of all three neuraminidase inhibitor was the same for the treatment of influenza virus infection in children.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Influenza Virus Products


CAS 3160-91-6 Moroxydine Hydrochloride

Moroxydine Hydrochloride
(CAS: 3160-91-6)

Moroxydine HCl is a synthetic antiviral compound chemically belonging to the series of the heterocyclic biguanidines.

CEF6

CEF6, one of the the CEF control peptides, is a 9-aa-long peptide corresponding to aa 418-426 of the influenza A virus (H1N1) nucleocapsid protein.

CAS 204255-11-8 Oseltamivir Phosphate

Oseltamivir Phosphate
(CAS: 204255-11-8)

Oseltamivir phosphate (Tamiflu) is a competitive neuraminidase inhibitor. The prodrug oseltamivir phosphate (Tamiflu) is itself not virally effective.

CAS 131707-23-8 Arbidol Hydrochloride

Arbidol Hydrochloride
(CAS: 131707-23-8)

Arbidol HCl is an antiviral treatment for influenza infection.

CAS 1629869-44-8 VX-787

VX-787
(CAS: 1629869-44-8)

VX-787, a pyrrolopyridine derivative, has been found to be an antiviral agent and is still under Phase II trial against Influenza A virus infection.

CAS 187227-45-8 Oseltamivir acid

Oseltamivir acid
(CAS: 187227-45-8)

Oseltamivir acid is the active metabolite of oseltamivir. Oseltamivir, also called as GS 4071 or Ro 64-0802, is an antiviral drug that competitively inhibits ne...

CAS 139110-80-8 Zanamivir

Zanamivir
(CAS: 139110-80-8)

Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.

CAS 13392-28-4 Rimantadine

Rimantadine
(CAS: 13392-28-4)

Rimantadine, an adamantane derivative, could be an effective antiviral drug and probably prevent influenza virus at some extent.

Chemical Structure

CAS 139110-80-8 Zanamivir

Quick Inquiry

Verification code

Featured Items